SG/PUT/BRISTOL-MYERS SQUIBB/80/0.1/21.06.24 | Delayed Deutsche Boerse AG 08:36:24 22/05/2024 BST | ||
| 3.43 EUR | -0.87% |
|
| Current month | +3.28% | ||
| 1 month | +18.49% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 22/05/24 | 3.43 | -0.87% |
| 21/05/24 | 3.46 | +2.98% |
| 20/05/24 | 3.36 | +1.82% |
| 17/05/24 | 3.3 | +0.30% |
| 16/05/24 | 3.29 | +1.23% |
Delayed Quote Deutsche Boerse AG
Last update May 22, 2024 at 08:36 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SQ6K9W |
| ISIN | DE000SQ6K9W9 |
| Date issued | 20/12/2022 |
| Strike | 80 $ |
| Maturity | 21/06/2024 (31 Days) |
| Parity | 10 : 1 |
| Emission price | 1.08 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.46 € |
|---|---|
| Lowest since issue | 0.89 € |
| Spread | 0.05 € |
| Spread % | 1.43% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
42.27
USD
Average target price
53.19
USD
Spread / Average Target
+25.84%
- Stock Market
- Warrants
- Warrant
